Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China; State Key Laboratory of Natural and Biomimetic Drugs, Beijing 100191, China.
Adv Drug Deliv Rev. 2017 Jun 1;115:23-45. doi: 10.1016/j.addr.2017.03.001. Epub 2017 Mar 7.
Combination therapy is one of the important treatment strategies for cancer at present. However, the outcome of current combination therapy based on the co-administration of conventional dosage forms is suboptimal, due to the short half-lives of chemodrugs, their deficient tumor selectivity and so forth. Nanotechnology-based targeted delivery systems show great promise in addressing the associated problems and providing superior therapeutic benefits. In this review, we focus on the combination of therapeutic strategies between different nanomedicines or drug-loaded nanocarriers, rather than the co-delivery of different drugs via a single nanocarrier. We introduce the general concept of various targeting strategies of nanomedicines, present the principles of combination antitumor therapy with dual-nanomedicines, analyze their advantages and limitations compared with co-delivery strategies, and overview the recent advances of combination therapy based on targeted nanomedicines. Finally, we reviewed the challenges and future perspectives regarding the selection of therapeutic agents, targeting efficiency and the gap between the preclinical and clinical outcome.
联合治疗是目前癌症的重要治疗策略之一。然而，由于化疗药物半衰期短、肿瘤选择性差等原因，目前基于常规剂型联合用药的联合治疗效果并不理想。基于纳米技术的靶向递药系统在解决相关问题和提供更好的治疗效果方面具有很大的潜力。在本文中，我们主要关注不同纳米药物或载药纳米载体之间的治疗策略联合，而不是通过单个纳米载体共递不同的药物。我们介绍了各种纳米药物靶向策略的一般概念，提出了双纳米药物联合抗肿瘤治疗的原则，分析了与共递药策略相比的优缺点，并综述了基于靶向纳米药物的联合治疗的最新进展。最后，我们讨论了治疗药物选择、靶向效率以及临床前和临床结果之间差距方面的挑战和未来展望。
Zotero 插件